| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
,¶
Divisions of
*
Immunology, Allergy, and Infectious Diseases and
Special and Environmental Dermatology, Department of Dermatology, and
Department of Blood Group Serology, University of Vienna Medical School, Vienna, Austria;
CeMM-Center of Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria;
¶ Department of Pathology, Harvard Medical School, Boston, MA 02115; and
|| Research Institute of Molecular Pathology, Vienna, Austria
Therapeutic vaccination against cutaneous T cell lymphoma (CTCL) requires the characterization of cancer cell-specific CTL epitopes. Despite reported evidence for tumor-reactive cytotoxicity in CTCL patients, the nature of the recognized determinants remains elusive. The clonotypic TCR of CTCL cells is a promising candidate tumor-specific Ag. In this study, we report that the clonotypic and framework regions of the TCRs expressed in the malignant T cell clones of six CTCL patients contain multiple peptides with anchor residues fitting the patients’ MHC class I molecules. We demonstrate that TCR peptide-specific T cells from the blood of healthy donors and patients can be induced to become cytotoxic effectors after repeated stimulation with 6 of 11 selected peptides with experimentally proven affinity for HLA-A*0201. Importantly, 4 of these 6 CTL lines reproducibly recognize and lyse autologous primary CTCL cells in MHC class I/CD8-dependent fashion. These tumoricidal CTL lines are directed against epitopes from V, hypervariable, and C regions of TCR
. We therefore conclude that recombined as well as V framework regions of the tumor cell TCRs contain predictable epitopes for CTL-mediated attack of CTCL cells. Our data further suggest that such peptides represent valuable tools for future anti-CTCL vaccination approaches.
This article has been cited by other articles:
|
|
 |
|
  D. Winter, J. Moser, E. Kriehuber, C. Wiesner, R. Knobler, F. Trautinger, P. Bombosi, G. Stingl, P. Petzelbauer, A. Rot, et al. Down-Modulation of CXCR3 Surface Expression and Function in CD8+ T Cells from Cutaneous T Cell Lymphoma Patients J. Immunol., September 15, 2007; 179(6): 4272 - 4282. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. L. Berger, R. Tigelaar, J. Cohen, K. Mariwalla, J. Trinh, N. Wang, and R. L. Edelson Cutaneous T-cell lymphoma: malignant proliferation of T-regulatory cells Blood, February 15, 2005; 105(4): 1640 - 1647. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Girardi, P. W. Heald, and L. D. Wilson The Pathogenesis of Mycosis Fungoides N. Engl. J. Med., May 6, 2004; 350(19): 1978 - 1988. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
